Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma (PPCB) reported preclinical pancreatic cancer results for PRP, including more than 90% mean tumor growth inhibition versus vehicle.
In advanced pancreatic ductal adenocarcinoma models, intravenous PRP extended median overall survival more than 2.5-fold versus controls, reduced liver and peritoneal metastases, and reduced fibrosis and markers of epithelial-mesenchymal transition, a change in cell behavior. Chemotherapy-resistant cells became more sensitive to gemcitabine plus nab-paclitaxel. PRP has FDA orphan drug designation for pancreatic cancer. Propanc sees it as a potential combination or sequential partner, rather than a substitute, for the FDA-approved RAS inhibitor daraxonrasib.
The company plans a Phase 1b first-in-human study in Q1 2027, expected to enroll up to 50 advanced solid-tumor patients across Australia. Prior compassionate-use observations involved related proenzyme formulations.
Propanc Biopharma (PPCB) reported a narrower annual loss and outlined plans for a Phase 1b study of PRP. The study is planned to start in the first quarter of 2027, with a first patient visit scheduled for April. It would enroll up to 50 patients with advanced solid tumors in Australia. In animal models of pancreatic cancer, PRP produced greater than 90% mean tumor growth inhibition versus controls and extended median survival by more than 2.5-fold.
For the year ended June 30, 2026, net loss narrowed to $18,862,710 from $58,923,300; revenue remained at zero. Annual gross proceeds raised totaled $7.5 million, including a public offering of 1,000,000 shares at $4.00 each. Cash stood at $832,006 at June 30, and a further $2.0 million was received from the Series C facility afterward. Total liabilities fell to $3,378,251 from $5,725,616. Propanc also authorized up to $5.0 million in share repurchases and completed a $500,000 first tranche.
Propanc Biopharma (PPCB) reported new preclinical pancreatic ductal adenocarcinoma (PDAC) data for its lead candidate PRP, showing more than 90% mean tumor-growth inhibition and over 2.5-fold median overall survival extension versus controls in orthotopic and patient-derived xenograft models.
PRP, an intravenous fixed-ratio proenzyme combination, is described as non-cytotoxic and differentiation-based, targeting epithelial-mesenchymal transition, cancer stem cells, fibrosis, and the tumor microenvironment rather than RAS itself. The company contrasts this profile with Erasca’s oral pan-RAS molecular glue ERAS-0015 and daraxonrasib, positioning PRP as potentially complementary. PRP holds FDA Orphan Drug Designation for pancreatic cancer, with a multicenter Phase 1b first-in-human study in advanced solid tumors planned to start dosing in February 2027.
Propanc Biopharma (PPCB) plans to start a world-first Phase 1b first-in-human study of its lead candidate PRP in February 2027.
The multicenter, open-label trial in Australia will enroll up to 50 patients with advanced solid tumors, using a two-part design with dose escalation followed by dose expansion. The study will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. GMP manufacturing of PRP, PK method validation, anti-drug antibody assay development, and preparation for a Human Research Ethics Committee submission targeted for November 2026 are underway.
Propanc Biopharma (Nasdaq:PPCB) reported new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models, three-times-weekly intravenous PRP achieved >90% mean tumor growth inhibition versus vehicle controls (p < 0.001), markedly reduced liver and peritoneal metastases, remodeled the tumor microenvironment, and enhanced sensitivity of chemo‑resistant PDAC cells to gemcitabine/nab‑paclitaxel. According to Propanc, treated animals showed a median overall survival extension of more than 2.5‑fold versus controls, building on prior >85% inhibition data and compassionate‑use experience suggesting prolonged survival with a favorable safety profile. PRP, a fixed‑ratio combination of trypsinogen and chymotrypsinogen, has FDA Orphan Drug Designation for pancreatic cancer and is not limited to specific RAS mutations. The company is advancing GMP manufacturing, assay validation, and partnerships to support a planned Phase 1b First‑in‑Human study in approximately 40–45 patients with advanced solid tumors, with a clinical trial application expected in the coming months.
Propanc Biopharma (Nasdaq: PPCB) has begun finalizing the clinical trial protocol and conducting a feasibility assessment for a First‑In‑Human, Phase 1b study of its lead candidate PRP in up to 40 patients with advanced solid tumors across multiple centers in Australia.
Avance Clinical will lead preparatory activities, including reviewing the Investigator’s Brochure, preparing a Briefing Document, and finalizing the Clinical Trial Protocol. The open‑label study will use a two‑part dose escalation and expansion design, with weekly IV dosing and a BOIN approach to identify maximum tolerated and recommended doses. A Clinical Trial Application submission is planned for Q4 this year.
Propanc Biopharma (Nasdaq: PPCB) outlined how its lead candidate PRP, a fixed‑ratio combination of pancreatic proenzymes trypsinogen and chymotrypsinogen, may address aggressive, RAS‑driven solid tumors such as pancreatic ductal adenocarcinoma (PDAC) by promoting differentiation, reversing epithelial‑mesenchymal transition (EMT), and targeting cancer stem cells.
Administered once weekly by IV, PRP showed >90% mean tumor growth inhibition, marked metastasis reduction, and >2.5‑fold median survival extension in advanced PDAC preclinical models, and holds FDA Orphan Drug Designation for pancreatic cancer. Propanc plans a Phase 1b first‑in‑human study in 40–45 advanced solid‑tumor patients, with GMP manufacturing and clinical partnerships advancing in 2026. The company contrasts PRP’s non‑cytotoxic, phenotype‑reprogramming approach with pathway‑centric RAS inhibitors from Revolution Medicines and Erasca, positioning PRP as potentially complementary for long‑term, low‑toxicity treatment.
Propanc Biopharma (Nasdaq: PPCB) reported new preclinical and early translational results for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models of advanced PDAC, 3x-weekly intravenous PRP achieved >90% mean tumor growth inhibition versus vehicle controls, marked metastatic burden reductions in liver and peritoneum, and a median overall survival extension of more than 2.5-fold in treated animals.
According to Propanc, PRP also remodeled the tumor microenvironment and enhanced sensitivity of chemo‑resistant PDAC cells to gemcitabine/nab‑paclitaxel. The company plans to accelerate a Phase 1b first‑in‑human study in approximately 30–40 advanced solid‑tumor patients, targeting clinical trial application submission in Australia in the coming months. PRP has FDA Orphan Drug Designation for pancreatic cancer, with GMP manufacturing targeted for late 2026 and a memorandum of understanding with Avance Clinical to support trial execution.
Propanc Biopharma (Nasdaq: PPCB) announced completion of the first $500,000 tranche of its previously approved $5.0 million share repurchase program, executed within the first 30 days of commencement. The company said it intends to continue buybacks under Rule 10b5-1, using methods such as open market and privately negotiated transactions, with no obligation to repurchase a specific number of shares.
Management stated it views Propanc as significantly undervalued as it advances a planned world-first Phase 1b, first-in-human study of its lead candidate PRP in approximately 40–45 advanced solid tumor patients in Australia. The repurchase program may be modified, discontinued, or suspended at any time.
Propanc Biopharma (Nasdaq: PPCB) announced publication of joint research with the Universities of Jaén and Granada in peer‑reviewed journal Microbial Cell Factories, evaluating recombinant trypsinogen and chymotrypsinogen for biotechnology applications, including potential human therapeutic use against chronic diseases such as cancer and fibrosis.
According to Propanc, the work supports scalable production of stable, purified recombinant proenzymes forming a backup candidate, rec‑PRP, to its bovine‑derived lead asset PRP, which is targeting a Phase 1b first‑in‑human study in advanced solid tumor patients in early 2027. Rec‑PRP is planned for small‑scale, non‑GMP production to compare with PRP and define a clinical regulatory pathway, and may offer long shelf life without refrigeration, aiding global distribution.